CPIC 2026 | Brain-Computer Interface: Showmanship Won't Win
Exclusive Interview with Tao Hu, Founder, CEO & Chief Scientist of NeuroXess
Time：
2026-08-08 17:55
Author：
xieyijun
FDA's "Clinical Ban" on China Stalls
China is becoming one of the world's sources of new drug discovery.
Time：
2026-08-07 19:24
Author：
xieyijun
From Spotlight to Silence: Behind Another Gene Editing Death
Time：
2026-08-06 17:52
Author：
xieyijun
CPIC 2026 | Opening a New "Silk Road" for China-Europe Innovative Drug Collaboration
Embedding China's Speed into Europe's Precision Calibration.
Time：
2026-08-04 19:36
Author：
xieyijun
From Local to Global: How Does Bayer Resonate with China's Innovation?
Exclusive Interview with Kendra Rose, SVP of BD at Bayer
Time：
2026-08-03 18:22
Author：
xieyijun
Talent Aesthetics: An Neglected Management Ability (Part One)
Biopharmaceuticals, a place that requires the most aesthetic talents
Time：
2026-08-01 19:40
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务